- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 241/12
Total number of patents in this class: 485
10-year publication summary
46
|
47
|
34
|
53
|
39
|
42
|
36
|
39
|
24
|
15
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Semiconductor Energy Laboratory Co., Ltd. | 11398 |
13 |
Bristol-myers Squibb Company | 4878 |
10 |
Amgen Inc. | 4072 |
10 |
Guangzhou Magpie Pharmaceuticals Co., Ltd. | 29 |
10 |
Abbvie Inc. | 1802 |
8 |
Merck Sharp & Dohme LLC | 3750 |
8 |
Calico Life Sciences LLC | 96 |
7 |
F. Hoffmann-La Roche AG | 7930 |
6 |
Hoffmann-La Roche Inc. | 3414 |
6 |
Massachusetts Institute of Technology | 10051 |
6 |
The General Hospital Corporation | 4726 |
6 |
Arcus Biosciences, Inc. | 138 |
6 |
The Broad Institute, Inc. | 1805 |
6 |
Nippon Soda Co., Ltd. | 894 |
6 |
Novartis AG | 10847 |
5 |
The Regents of the University of California | 19898 |
5 |
Syngenta Crop Protection AG | 6045 |
5 |
Bayer Pharma AG | 1053 |
5 |
Novaled GmbH | 441 |
5 |
Vivace Therapeutics, Inc. | 30 |
5 |
Other owners | 347 |